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Abstract
Background: Chronic obstructive pulmonary disease (COPD) is related to endothelial dysfunction and the impaired
generation of nitric oxide (NO) from L-arginine by the endothelial NO synthase (eNOS). The relationship between
eNOS dysfunctionality and airway inflammation is unknown. We assessed serum asymmetric and symmetric
dimethylarginine (ADMA and SDMA) and nitrite/nitrate concentrations, indicators of eNOS function, in patients
with COPD and correlated them with markers of inflammation.
Methods: We recruited 15 control smokers, 29 patients with stable and 32 patients with exacerbated COPD
requiring hospitalization (20 of them were measured both at admission and discharge). Serum L-arginine,
ADMA, SDMA, nitrite and nitrate were measured and correlated with airway inflammatory markers (fractional
exhaled nitric oxide concentration - FENO, sputum nitrite and nitrate, sputum cellularity), serum C-reactive
protein - CRP, white blood cell count, lung function and blood gases. ANOVA, t-tests and Pearson correlation
were used (mean ± SD or geometric mean ± geometric SD for nitrite/nitrate).
Results: Serum L-arginine/ADMA, a marker of substrate availability for eNOS, was lower in stable (214 ± 58,
p < 0.01) and exacerbated COPD (231 ± 68, p < 0.05) than in controls (287 ± 64). The serum concentration of
SDMA, a competitor of L-arginine transport, was elevated during an exacerbation (0.78 ± 0.39 μM) compared
to stable patients (0.53 ± 0.14 μM, p < 0.01) and controls (0.45 ± 0.14 μM, p < 0.001). ADMA correlated with blood
neutrophil percentage (r = 0.36, p < 0.01), FENO (r = 0.42, p < 0.01) and a tendency for positive association was observed
to sputum neutrophil count (r = 0.33, p = 0.07). SDMA correlated with total sputum inflammatory cell count (r = 0.61,
p < 0.01) and sputum neutrophil count (r = 0.62, p < 0.01). Markers were not related to lung function, blood gases or
CRP. L-arginine/ADMA was unchanged, but serum SDMA level decreased (0.57 ± 0.42 μM, p < 0.05) after systemic
steroid treatment of the exacerbation. Serum nitrite level increased in stable and exacerbated disease (4.11 ± 2.12 and
4.03 ± 1.77 vs. control: 1.61 ± 1.84 μM, both p < 0.001).
Conclusions: Our data suggest impaired eNOS function in stable COPD, which is transiently aggravated during
an exacerbation and partly reversed by systemic steroid treatment. Serum ADMA and SDMA correlate with
airway inflammatory markers implying a possible effect of anti-inflammatory therapy on endothelial dysfunction.
Serum nitrite can serve as a compensatory pool for impaired endothelial NO generation.
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Background
The prevalence of cardiovascular comorbidities includ-
ing ischemic heart disease, heart failure and arrhythmias
is higher in patients with chronic obstructive pulmonary
disease (COPD) than in the general population [1].
Patients with mild to moderate COPD already present
with endothelial dysfunction [2], which is linked with
higher arterial stiffness and excess cardiovascular risk
[3]. COPD is characterised by airway inflammation,
which leads to heightened systemic inflammation [4].
Studies on the association between systemic inflamma-
tion and endothelium-dependent vasodilation have pro-
vided contradictory findings [5, 6].
Endothelial dysfunction in COPD is related to the al-
tered expression and release of endothelium-derived
vasoactive mediators with the key involvement of nitric
oxide (NO) [7]. NO is a potent vasodilator, which is pro-
duced from L-arginine by the endothelial isoform of the
NO synthase (eNOS) [8]. It has a short half-life, and in
aqueous solutions it is decomposed to nitrite, while in
tissues NO and nitrite are enzymatically oxidized to
nitrate [9].
Protein methyltransferases methylate L-arginine resi-
dues, which undergo proteolysis to generate asymmetric
and symmetric dimethylarginine (ADMA and SDMA)
[10, 11]. These amino acids suppress NOS function as
ADMA is a competitive inhibitor of the enzyme, while
SDMA is a competitor for L-arginine transport. Their
roles in the pathomechanism of COPD have recently
been studied. Serum ADMA and SDMA but also L-
arginine concentrations are increased in COPD and fur-
ther elevated during an acute exacerbation [12]. Import-
antly, serum ADMA concentration is an independent
risk factor for long-term all-cause mortality in COPD
[13], and it is related to increased airway resistance [14].
Nonetheless, the link between the components of the
vascular NO pathway and airway inflammation in COPD
has not been explored.
Airway inflammation in COPD can non-invasively be
studied by the analysis of sputum and exhaled breath.
COPD is usually characterized by neutrophilia in spu-
tum and increased level of oxidative and nitrosative
stress markers in sputum supernatant [15, 16]. Epithelial
and inflammatory cells in COPD airways overexpress in-
ducible NOS (iNOS) [17, 18] to increase NO production
and nitrosative inflammation, which can be detected by
measuring the exhaled NO concentration [19].
We aimed to compare the serum concentrations of L-
arginine, ADMA, SDMA, nitrite and nitrate in patients
with stable and exacerbated COPD and smoking control
subjects. Measurements were repeated in the convales-
cence of the exacerbation by hospital discharge. In pa-
tients with COPD, we also assessed the associations of
these parameters with markers of airway (exhaled NO
level, sputum cellularity, sputum nitrite and nitrate
concentration) and systemic inflammation (serum C-
reactive protein concentration, blood leukocyte counts),
lung function variables and blood gas values.
Methods
Subjects
Patients with COPD were recruited between March
2016 and December 2017 at the Department of Pulmo-
nology, Semmelweis University, Budapest, Hungary.
COPD had previously been diagnosed by a respiratory
specialist according to Global Initiative for Chronic
Obstructive Lung Disease [20]. Patients presented with
stable disease (S-COPD, N = 29) or an acute severe ex-
acerbation requiring hospitalization (E-COPD, N = 32)
with symptoms of recent onset (< 72 h). COPD treat-
ment was unchanged for all patients and they were not
treated with systemic steroids or antibiotics in 4 weeks
prior to recruitment or hospital admission. Patients with
E-COPD did not require ventilatory support, did not
have concomitant pneumonia, and their therapy was de-
cided by the treating physician, but all patients received
oxygen supplementation, inhaled short-acting broncho-
dilators and systemic steroid. Control smoking subjects
(C) without respiratory symptoms in 4 weeks before
inclusion (> 40 years of age, > 10 pack-years) were re-
cruited among employees of the Department (N = 15).
Subjects were considered ex-smokers if they had stopped
smoking at least 6 months before inclusion. All proce-
dures were in accordance with the 1964 Helsinki declar-
ation and its later amendments. The study was approved
by the ethics committee and a written informed consent
was signed by all participants.
Study design
Control smokers and patients with S-COPD attended a
single visit, while patients with E-COPD were measured
within 24 h of hospital admission and when possible also
in convalescence (N = 20). Cardiovascular co-morbidities
(systemic hypertension, heart failure and cerebrovascular
accidents) were noted based on medical records and
self-report. White blood cell (WBC) count, serum CRP
concentration, post-bronchodilator lung function [20]
and fractional exhaled nitric oxide (FENO) were mea-
sured. Patients filled out the COPD Assessment test
(CAT) [21] and blood gases were determined. Serum
samples were collected from all subjects and stored at −
80 °C for later analysis. Patients gave spontaneous
sputum samples (S-COPD N = 13, E-COPD N = 17). Fur-
thermore, lung function and FENO measurements were
repeated in patients with E-COPD during convalescence
(< 24 h before hospital discharge), they filled in the CAT,
and second serum (N = 19) and sputum (N = 9) samples
were collected.
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Measurements
Routine blood tests
WBC and CRP concentrations were measured in venous
blood samples (Sysmex XN-1000, Sysmex Corporation,
Kobe, Japan and Beckman Coulter AU680, Beckman
Coulter Inc., Indianapolis, IN, USA). Blood gases and
pH were determined from arterial samples of patients
(S-COPD: N = 26, E-COPD: N = 30; Cobas b 21, Roche,
Switzerland).
Lung function tests
Lung function tests were performed according to
current guidelines (PDT-111, Piston, Budapest, Hungary)
[22, 23]. Spirometry was performed by all subjects.
Plethysmography was measured in most patients
(S-COPD N = 26, E-COPD N = 21).
FENO
Fractional exhaled NO concentration was measured at
50 mL/s constant expiratory according to current recom-
mendations (Sievers Nitric Oxide Analyzer i280, GE
Analytical Instruments, Boulder, Co, USA) [24]. The
mean values of two NO recordings with < 10% difference
were used for further calculations. All control subjects,
23 patients with stable COPD and 25 patients at the on-
set of an exacerbation could perform technically accept-
able manoeuvres.
Sputum processing
Samples were collected in the morning and processed
within 2 h as previously described [15, 25]. Briefly,
saliva-free samples were homogenized in 0.1% freshly
made dithiothreitol (Sigma-Aldrich, St Louis, MO, USA)
and filtered through a nylon mesh. The supernatant was
stored at − 80 °C for later analysis. Cells were counted in
a haemocytometer, and cell viability was assessed using
trypan blue exclusion. Cytospins were prepared and
Diff-Quik staining was used to express the differential
cell count of non-squamous cells.
Determination of serum L-arginine, ADMA and SDMA
The amino acids of the blood serum samples were ex-
tracted by solid-phase extraction [26] and then they
were derivatized [27]. High performance liquid chroma-
tographic analysis was performed with a Waters 2695
Separations Module equipped with a thermostable auto-
sampler (5 °C) and column module (35 °C). Separation
was achieved with a VDSpher PUR C18-M-SE, 5 μm,
150 × 4.6vmm HPLC Column and detected by a Waters
2475 fluorescence detector (Waters, Milford,MA, USA).
For the measurements, 10 μl sample was injected and
the gradient elution was applied according to Erdelyi-
Botor et al. [28]. The detection limit for L-Arginine was
0.1 μmol/L and it was 0.05 μmol/L for both ADMA and
SMDA [29].
Nitrite and nitrate measurements
The concentrations of nitrite and nitrate were measured
in serum samples and sputum supernatants according to
an established protocol [30]. In short, proteins in the
samples were destroyed by mixing them with 5 volumes
of 0.1M sodium hydroxide solution followed by neutral-
isation with an equal volume of 0.09M acetic acid and
heating in boiling water-bath for 3 min and centrifuga-
tion. The supernatants were analysed by capillary elec-
trophoresis using fused silica capillary and 30mM
sulfate-β-alanine buffer pH 3.8. Nitrate and nitrite were
separated using constant − 75 μA current and detected
by their UV absorbance at 214 nm. The detection
limits for nitrite and nitrate were 0.1 μM and 3 μM in
serum and 1 μM and 10 μM in sputum supernatant,
respectively.
Statistical analysis
Demographic data and serum parameters were analysed
with ANOVA and post-hoc test, and expressed as
mean ± standard deviation, except for serum CRP con-
centration and packyears, which were compared with
the Kruskal-Wallis test and expressed as median (inter-
quartile range). Categorical variables were compared
with the chi-square test. The values for FENO, sputum
cell count and sputum and serum nitrate and nitrite
concentrations were analysed with parametric tests after
logarithmic transformation (values of 0 were replaced by
0.01). Outcome parameters were correlated with demo-
graphical data, blood results, lung function and blood
gas values (Pearson or Spearman correlation). P < 0.05
was considered significant (GraphPad Prism 7.0, GraphPad
Software, San Diego, USA).
Results
Subjects
Patients were older and had more pack-years than con-
trol subjects (Table 1). Both COPD groups showed a
tendency for a higher prevalence of hypertension cases,
and the number of subjects with at least one cardiovas-
cular co-morbidity (hypertension, heart failure or
cerebrovascular event) was significantly higher in pa-
tients than in smoking controls (control: 33%, S-COPD:
72%, E-COPD: 75%, chi-square test: p = 0.01). Patients
with E-COPD had an increased blood leukocyte count
and elevated serum CRP level compared to stable pa-
tients. FENO was higher in patients with E-COPD than
in patients with stable COPD or smoking controls. The
maintenance inhaled regimens were similar between pa-
tients with stable and exacerbated disease. The sputum
profiles of patients with stable and exacerbated COPD
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showed a similar degree of neutrophilic airway inflam-
mation, which did not change at hospital discharge
(Table 2).
All patients with E-COPD received systemic cortico-
steroid treatment during hospitalization, and two-thirds
were also treated with antibiotics. At hospital discharge
(9 ± 3 days after admission), the CAT symptom score de-
creased (22 ± 8 vs. 17 ± 9, p = 0.03), and FEV1 increased
compared to the onset of the exacerbation (38 ± 13 vs.
49 ± 19% predicted, p = 0.02).
Serum L-arginine/ADMA and SDMA concentration
As ADMA is a competitive inhibitor of NOS, we
calculated serum L-arginine/ADMA which indicates L-
arginine availability for the enzyme [10]. L-arginine/
ADMA was decreased both in stable (p < 0.01) and exac-
erbated COPD (p < 0.05) compared to smoking controls
(C: 287 ± 64, S: 214 ± 58, E: 231 ± 68; ANOVA p < 0.01;
Fig. 1 a) and remained suppressed also at the recovery of
an acute relapse (243 ± 123; paired t-test, p = 0.89, Fig. 1b).
In patients with stable and exacerbated COPD, serum L-
arginine concentration showed a trend for positive correl-
ation with FENO (r = 0.28, p = 0.05), but not to other
clinical variables or sputum parameters (p > 0.1). Of note,
serum ADMA correlated with age (r = 0.25, p = 0.04),
blood neutrophil percentage (r = 0.36, p < 0.01; Fig. 1c)
and FENO (r = 0.42, p < 0.01; Fig. 1d) and a tendency
for a direct relationship was observed with sputum
neutrophil count (r = 0.33, p = 0.07).
Interestingly, the serum concentration of SDMA was
elevated only in E-COPD (0.78 ± 0.39 μM vs. C: 0.45 ±
0.14 μM and S-COPD: 0.53 ± 0.14 μM, p < 0.001 and p <
0.01; Fig. 2a) and it was lowered as a result of treating
the exacerbation (0.57 ± 0.42 μM, p < 0.05; Fig. 2b). At
the onset of an exacerbation, serum SDMA was posi-
tively correlated to age (r = 0.67, p < 0.001), total sputum
Table 1 Clinical characteristics of patients and controls
Control Stable Exacerbated p-value
COPD
Number (male) 15 (6) 29 (13) 32 (21) (0.15)
Age, years 51 ± 7 63 ± 8*** 63 ± 8*** < 0.001
Current/ex-smoker, N 12/3 20/9 19/13 0.36
Pack-years 30 (25–40) 50 (40–75)* 50 (31–78)* < 0.01
Systemic hypertension, N 5 18 21 0.10
Heart failure, N 0 4 3 0.32
Cerebrovascular event, N 1 2 4 0.70
ICS, N NA 18 25 0.26
LABA, N NA 28 29 0.61
LAMA, N NA 27 29 0.99
Oral theophylline, N NA 5 11 0.15
White blood cell count, G/L 9.4 ± 3.8 8.6 ± 2.9 11.1 ± 3.9# 0.02
CRP, mg/L 4 (2–6) 5 (2–10) 8 (3–14) 0.05
FEV1, % predicted 101 ± 14 47 ± 14*** 39 ± 13*** < 0.001
FVC, % predicted 109 ± 13 78 ± 19*** 65 ± 18***## < 0.001
FEV1/FVC 0.78 ± 0.08 0.49 ± 0.09*** 0.47 ± 0.09*** < 0.001
RV/TLC 0.31 ± 0.05 0.56 ± 0.12*** 0.58 ± 0.10*** < 0.001
Raw, kPa∙s∙L−1 0.24 ± 0.08 0.46 ± 0.15*** 0.46 ± 0.12*** < 0.001
pH NA 7.40 ± 0.03 7.41 ± 0.03 0.49
pO2, mmHg NA 60 ± 8 62 ± 10 0.29
pCO2, mmHg NA 43 ± 8 42 ± 7 0.61
CAT score NA 19 ± 7 21 ± 8 0.16
FENO, ppb 12 ± 2 14 ± 2 26 ± 3**# < 0.01
Data are presented as mean ± SD (geometric mean ± geometric SD for FENO) and compared with ANOVA and post-hoc test or chi-square test (categorical
variables) or shown as median (interquartile range) and analysed with Kruskal Wallis and Dunn’s post hoc test. CAT COPD Assessment Test, CRP C-reactive protein,
ICS inhaled corticosteroid, FENO fractional exhaled nitric oxide concentration, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, ICS inhaled corticosteroid,
LABA long-acting β2-agonist, LAMA long-acting muscarinic antagonist, N number, NA not applicable, pCO2 partial pressure of carbon dioxide in arterial blood, pO2 partial
pressure of oxygen in arterial blood, Raw airway resistance, RV residual volume, TLC total lung capacity. *p < 0.05, **p < 0.01, ***p < 0.001 vs. control, #p < 0.05,
##p < 0.01 vs. stable COPD
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inflammatory cell count (r = 0.61, p < 0.01; Fig. 2c) and
sputum neutrophil count (r = 0.62, p < 0.01; Fig. 2d).
Serum nitrate and nitrite concentration
Serum nitrate concentration was similar among smoking
control subjects and patients with stable or exacerbated dis-
ease (121 ± 2 μM, 79 ± 4 μM, 65 ± 5 μM p = 0.36, Fig. 3a),
and it showed no difference between the onset and the re-
covery of an exacerbation (47 ± 9 μM p= 0.87, Fig. 3b). Not-
ably, serum nitrite concentration was increased in patients
with stable and exacerbated COPD compared to smoking
control subjects (4.11 ± 2.12 μM and 4.03 ± 1.77 μM vs.
1.61 ± 1.84 μM, both p < 0.001, Fig. 3c), but it showed no
difference between hospital admission and discharge in pa-
tients with E-COPD (3.64 ± 1.63 μM p = 0.26, Fig. 3d).
When data of patients with stable and exacerbated
COPD were combined, serum nitrite concentration did
not show a correlation with sputum nitrate or nitrite
concentrations, FENO, age, pack-years, lung function or
blood parameters (p > 0.1 for all variables).
Table 2 Sputum characteristics in stable and exacerbated COPD
Stable COPD Exacerbated COPD
Onset Recovery
Total inflammatory cell count, 104/g sputum 193 (46–773) 202 (61–353) 157 (111–247)
Neutrophils, % 94 (84–95) 85 (70–94) 82 (60–92)
Neutrophils, 104/g sputum 182 (42–657) 196 (52–273) 107 (66–228)
Macrophages, % 5.3 (2.3–12) 9.0 (3.9–298) 8.0 (5.8–18)
Macrophages, 104/g sputum 9.4 (4.7–66) 12 (6.2–46) 13 (6.4–17)
Eosinophils, % 1.5 (0–3.6) 0.8 (0.2–4.6) 0.1 (0–0.5)
Eosinophils, 104/g sputum 2.9 (0–11.8) 1.1 (0.1–3.5) 0.1 (0–3.2)
Lymphocytes, % 0.3 (0–0.8) 0.2 (0–0.7) 0.1 (0–0.8)
Lymphocytes, 104/g sputum 0.2 (0–2.2) 0.1 (0–1.1) 0.1 (0–0.2)
Groups were compared with unpaired t-test (stable vs. exacerbated at onset) or paired t-test (within exacerbation) after logarithmic transformation. Data are shown
as median (interquartile range). All p values were > 0.10
Fig. 1 Serum L-arginine/ADMA in smoking controls and patients with COPD. Serum L-arginine/ADMA was analysed among smoking control and
patients with stable and exacerbated COPD (a, ANOVA with post-hoc test) and between the onset and the recovery of an acute severe exacerbation
(b, paired t-test). Correlation between serum ADMA concentration and blood neutrophil percentage and FENO was also analysed in patients with
stable and exacerbated COPD (c and d, Pearson correlation). Control: smoking control subjects, S-COPD: stable COPD, E-COPD: exacerbation of COPD,
FENO: fractional exhaled nitric oxide concentration. *p < 0.05, **p < 0.01 vs. Control. Data are shown as mean and standard deviation
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Fig. 2 Serum SDMA concentration in smoking controls and patients with COPD. Serum SDMA concentration was compared among smoking
controls and patients with stable and exacerbated COPD (a, ANOVA) and between the onset and the recovery of an acute severe exacerbation
(b; paired t-test). Correlation between serum SDMA concentration and sputum inflammatory cell count and neutrophil count was also analysed in
patients with E-COPD (c and d, Pearson correlation). Control: smoking control subjects, S-COPD: stable COPD, E-COPD: exacerbation of COPD.
**p < 0.01, ***p < 0.001 vs. Control. ##p < 0.01 vs. S-COPD, &p < 0.05 vs. Onset. Data are shown as mean and standard deviation
Fig. 3 Serum nitrate and nitrite concentration in smoking controls and patients with COPD. Logarithmically transformed serum nitrate and nitrite
concentrations were analysed among smoking control and patients with stable and exacerbated COPD (a and c; ANOVA with post-hoc analysis,
***p < 0.001) and between the onset and the recovery of an acute severe exacerbation (b and d; paired t-test). Control: smoking control subjects,
S-COPD: stable COPD, E-COPD: exacerbation of COPD. Data were analysed after log transformation and are shown as geometric mean and geometric
standard deviation
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Sputum nitrate and nitrite concentrations in COPD
Sputum nitrate concentration was higher during a re-
lapse than in stable condition (205 ± 2 μM vs. 87 ± 3 μM,
p < 0.05; Fig. 4a) and was decreased at recovery after ad-
equate treatment (81 ± 3 μM; Fig. 4b). In contrast, spu-
tum nitrite concentration was not changed at an
exacerbation compared to the stable state (14.59 ±
1.97 μM vs. 21.74 ± 2.41 μM, p = 0.17; Fig. 4c), and no
difference was observed between the onset and recovery
of a relapse, either (15.02 ± 1.58 μM, p = 0.88, Fig. 4d).
Discussion
Endothelial dysfunction potentially links cardiovascular
comorbidities and COPD [1, 31]. In the present study,
we found that serum L-Arginine/ADMA ratio is de-
creased, while serum SDMA level is increased in stable
and exacerbated COPD, which can contribute to the im-
paired vascular NO generation and endothelial dysfunc-
tion. Importantly, we showed for the first time that
serum ADMA and SDMA concentrations correlate with
airway nitrosative stress and neutrophilic inflammation
suggesting an association between endothelial dysfunc-
tion and airway inflammation in COPD.
The mechanism of vascular wall damage in COPD is
not fully understood. Endothelial dysfunction is a com-
ponent of vascular damage, which has been described as
an early signal of increased cardiovascular risk [32].
Nitric oxide generated in the endothelium plays an im-
portant role in controlling the vascular tone in COPD.
Flow-mediated dilatation (FMD) of the brachial artery, a
marker of attenuated NO-mediated vasodilation and
endothelial dysfunction, is impaired in patients with
COPD [5]. Furthermore, in a cohort of patients with di-
verse COPD severity and prevalent cardiovascular co-
morbidities, worse FMD was associated with lower
FEV1% predicted and lower daily physical activity [6].
The current study contributes to these findings, by
showing that impaired endothelial NO signalling relates
to airway inflammation.
It was demonstrated that in COPD the biosynthesis of
NO is attenuated in the endothelium [7]. Indeed, the
serum concentration of the competitive eNOS inhibitor
ADMA was shown to be increased in COPD [12]. We
extend these findings by proving that serum L-arginine/
ADMA ratio, a marker of substrate availability for
eNOS, is decreased in stable and exacerbated disease at
a similar extent. Importantly, serum ADMA in COPD
showed a relationship to systemic (blood neutrophilia)
and airway (sputum neutrophilia and exhaled NO)
markers of inflammation. Of note, adequate treatment of
COPD exacerbation did not modify serum L-arginine/
ADMA ratio implying a permanent dysfunction inde-
pendent of the clinical state of COPD. The mean in-
crease in serum ADMA concentration was 0.1 μM and
Fig. 4 Sputum nitrate and nitrite concentration in COPD. Sputum nitrate and nitrite concentrations were analysed between patients with stable
and exacerbated COPD (a and c; unpaired t-test, *p < 0.05), and between the onset and the recovery of an acute severe exacerbation (b and d;
paired t-test, &p = 0.06). S-COPD: stable COPD, E-COPD: exacerbation of COPD. Data were analysed after log transformation and are shown as
geometric mean and geometric standard deviation
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0.2 μM in patients with stable and exacerbated COPD,
respectively (data not shown), which could already
induce circulatory effects [33], and it is in the range
associated with an increased risk of cardiovascular
death [34].
We measured increased serum concentrations of
SDMA in COPD only during an exacerbation, suggest-
ing that eNOS functionality is further and transiently
inhibited during a flare-up. In line with this, COPD
relapses, especially those requiring hospitalization,
convey an increased risk of cardiovascular events [35].
Importantly, serum SDMA was associated with the
burden of airway neutrophilia also highlighting a pos-
sible link between eNOS dysfunction and airway pro-
cesses in COPD.
Our findings suggest that drugs targeting airway in-
flammation might have a beneficial effect on endothelial
dysfunction in COPD by increasing eNOS functionality.
In support, it was demonstrated that ICS treatment
might reduce the risk of acute myocardial infarction in
patients with COPD [36], and arterial stiffness can be
improved by ICS/LABA therapy [37]. Likewise, we also
showed that an increase in serum SDMA concentration
during E-COPD is reversed in parallel to a decrease in
airway inflammation (reduced sputum nitrate concentra-
tion and FENO) as a result of systemic steroid therapy.
We did not find a correlation between ADMA, SDMA
and lung function, blood gas parameters or serum CRP.
This is in line with the findings of Clarenbach et al., who
did not describe an association between endothelial dys-
function and markers of systemic inflammation and oxi-
dative stress, hypoxaemia, age, current smoking and
pack-years in patients with stable COPD [6]. However,
in our study age correlated with both parameters, which
support data from a previous study showing that ADMA
and SDMA are involved in endothelial dysfunction in an
ageing population [38].
The serum concentration of nitrite was elevated both
in stable and exacerbated COPD. Nitrite can serve as a
pool for NO as it can be converted into nitric oxide by
deoxyhemoglobin-mediated reduction in acidosis or
hypoxaemia, which are often present in COPD [39]. In
line with this, the generation of nitrite and then NO
from dietary supplements rich in inorganic nitrate re-
sults in a decrease in systemic blood pressure in patients
with COPD [40]. This mechanism can contribute to in-
creasing serum nitrite level in COPD and can presum-
ably result in local NO production in the vasculature to
compensate for the attenuated eNOS activity.
Airway activity of the inducible NOS is increased in
stable COPD [18], resulting in the increased level of airway
nitrite and nitrate [41]. We have previously shown that dur-
ing an exacerbation the increased nitrosative stress burden
can be measured as elevated NO concentration in the
exhaled breath [19]. This is extended by the present find-
ings that sputum nitrate concentration is also increased
during exacerbation. Serum ADMA concentration in
COPD correlated with FENO, but not with sputum nitrate
or nitrite levels. This can be explained by the multi-fold re-
actions of NO in COPD airways including the generation
of nitrite/nitrate and peroxynitrite, or its reaction with tyro-
sine residues.
We cannot exclude that the increased serum nitrite
concentration might be related to increased iNOS activ-
ity of circulating and vascular cells in COPD and that
the altered concentration of serum ADMA and SDMA
might also modulate iNOS function on these cells. Blood
lymphocytes showed increased iNOS activity in COPD
[42], however, neutrophil granulocytes, present in ele-
vated number in patients, did not show iNOS activity in
healthy humans [43] with no data available in patients
with COPD. In addition, pulmonary arteries showed de-
creased eNOS, but increased iNOS expression in pa-
tients with end-stage disease [44], but it was not
confirmed by another study [45].
Our study also has limitations. It would have been
relevant to measure endothelial dysfunction using
physiological tests and correlate results with serum
markers of the NO pathway and their changes during an
exacerbation. Furthermore, despite repeated efforts, we
could not obtain a sputum sample or a valid exhaled
NO measurement in all patients. We did not perform
sputum induction and only collected spontaneous sam-
ples as sputum induction might convey increased risk
during an exacerbation. Samples were obtained from ex-
acerbated patients within 24 h after hospital admission,
when all patients received at least one dose of systemic
steroid, which could confound the results of the serum
and sputum analysis.
Conclusions
This is the first study to describe a connection between
airway inflammation and impaired endothelial NOS ac-
tivity, a known mechanism involved in endothelial dys-
function in COPD. We found that the substrate
availability for eNOS (reflected by L-arginine/ADMA) is
decreased in stable and exacerbated COPD, while SDMA
is transiently elevated during a relapse. ADMA and
SDMA showed correlations to airway inflammatory
markers including exhaled nitric concentration, sputum
inflammatory and neutrophil cell counts. Our findings
confirm impaired eNOS function in COPD and suggest
the potential modulation of the vascular NO signalling
by the suppression of airway inflammation.
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